glp-1 and kidney cancer Glucagon-like Peptide Receptor Agonists Outcomes in the Era of Personalized Medicine: Focus on Albuminuria Renal effects of GLP-1 receptor

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al

CHICAGO (February 2, 2026) With over 31 million people currently using GLP-1 drugs like Ozempic and Mounjaro, the conversation has shifted from weight loss success stories to serious legal questions

Patients benefit from continuing their existing acid-suppression therapy while beginning GLP-1 treatment

Animal studies have shown potential risks to the developing baby, and human pregnancy data are very limited

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness